BioAtla Reports Fourth Quarter and Full Year 2023 Financial

CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data...

Related Keywords

United States , Beijing , China , San Diego , California , American , Richard Waldron , Mecbotamab Vedotin , Ozuriftamab Vedotin , Bruce Mackle , Nasdaq , Rare Cancers Congress , Bioatla Inc , American Association For Cancer Research , Exchange Commission , Lifesci Advisors , Office Of Orphan Products Development , Conditionally Active Biologic , Chief Executive Officer , Operational Updates , Rare Cancers , Rare Cancers Congress March , Scientific Meeting March , American Association , Cancer Research , Conditionally Active Biologics , Meeting April , Conditional Active Biologic , Full Year , Orphan Products Development , Orphan Drug Designation , Annual Report , Sci Advisors ,